- Conditions
- Parkinson Disease, Tremor, Dyskinesias
- Interventions
- Cerebellothalamic optimized deep brain stimulation, Pallidothalamic optimized deep brain stimulation, No deep brain stimulation, Usual care deep brain stimulation
- Device · Other
- Lead sponsor
- Duke University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2027
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–13
of 13
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Parkinson Disease
- Interventions
- Gait tests with and without the use of a tactile sensory cue (electrical stimulation using a TENS unit)
- Device
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 4 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2009
- U.S. locations
- 1
- States / cities
- St Louis, Missouri
- Conditions
- Parkinson Disease
- Interventions
- Active NIR-PBM (MedX 1116, MCT502), Sham NIR-PBM (MedX 1116, MCT502)
- Device
- Lead sponsor
- University of Florida
- Other
- Eligibility
- 62 Years to 89 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2022
- U.S. locations
- 1
- States / cities
- Gainesville, Florida
- Conditions
- Parkinson Disease
- Interventions
- 150% of their routine home dopaminergic medications dose right in the clinic, Evaluation of mathematical models
- Drug · Device
- Lead sponsor
- Stardots AB
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2027
- U.S. locations
- 1
- States / cities
- Manchester, New Hampshire
- Conditions
- Parkinson's Disease, Motor Symptoms, Akinesia, Hypomobility, Delayed Levodopa Onset
- Interventions
- APOKYN, L-dopa, Trimethobenzamide
- Drug
- Lead sponsor
- MDD US Operations, LLC a subsidiary of Supernus Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 127 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 12
- States / cities
- Los Angeles, California • Reseda, California • Washington D.C., District of Columbia + 9 more
- Conditions
- Restless Legs Syndrome
- Interventions
- Horizant
- Drug
- Lead sponsor
- University of Missouri-Columbia
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 10 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2019
- U.S. locations
- 1
- States / cities
- Columbia, Missouri
- Conditions
- Parkinson Disease
- Interventions
- Upper limb feeding training
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 23 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Parkinson Disease, Gait Disorders, Neurologic, Disease Progression, Subthalamic Nucleus, Accidental Fall, Deep Brain Stimulation
- Interventions
- High-Frequency-Only Stimulation, Low-Frequency-Only Stimulation, Alternating, 50 sec High-Frequency, 10 sec Low-Frequency Stimulation, Alternating, 50 sec High-Frequency, 50 sec Low-Frequency Stimulation, Alternating, 10 sec High-Frequency, 50 sec Low-Frequency Stimulation, Alternating, 10 sec High-Frequency, 10 sec Low-Frequency Stimulation, OFF Dopaminergic Medication, ON Dopaminergic Medication
- Device · Drug
- Lead sponsor
- James Liao
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 12 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Parkinson Disease, Gait Disorders, Neurologic, Parkinsonian Disorders, Movement Disorders, Gait, Unsteady, Gait, Festinating
- Interventions
- No Cue, Conventional Cue, Constant Cue, Patient hand-triggered, Patient eye-triggered, Examiner-triggered
- Other
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum and Other Psychotic Disorders, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depression, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010 156 mg treatment group, deltoid, LY03010 156 mg treatment group, gluteal, LY03010 351 mg treatment group, deltoid, LY03010 351 mg treatment group, gluteal
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 89 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Little Rock, Arkansas • Garden Grove, California • Orange, California + 6 more
- Conditions
- Parkinson Disease
- Interventions
- Stepping training
- Behavioral
- Lead sponsor
- University of Utah
- Other
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2017
- U.S. locations
- 1
- States / cities
- Salt Lake City, Utah
- Conditions
- Schizophrenia, Psychotic Disorders, Mood Disorders, Schizophrenia Spectrum, Mental Disorders, Antipsychotic Agents, Tranquilizing Agents, Central Nervous System Depressants, Physiological Effects of Drugs, Psychotropic Drugs, Neurotransmitter Agents, Molecular Mechanisms of Pharmacological Action
- Interventions
- LY03010; paliperidone palmitate, INVEGA SUSTENNA
- Drug
- Lead sponsor
- Luye Pharma Group Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 281 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2022
- U.S. locations
- 9
- States / cities
- Garden Grove, California • Lemon Grove, California • Torrance, California + 6 more
- Conditions
- Parkinson's Disease
- Interventions
- Detailed motor testing, including FoG, in PD subjects
- Other
- Lead sponsor
- VA Office of Research and Development
- Federal
- Eligibility
- 50 Years and older
- Enrollment
- 53 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 1
- States / cities
- Ann Arbor, Michigan